Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2011Proceedings of the National Academy of Sciences

Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJianda YuanMAMatthew AdamowBGBrian Ginsberg

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yuan et al. (2011) studied this question.

synapsesocial.com/papers/69deaabd40ea065679558f88https://doi.org/10.1073/pnas.1110814108
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens1998 · 701 citations
  2. 2Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients2008 · 652 citations
  3. 3Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer2009 · 815 citations
  4. 4Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming2007 · 296 citations
  5. 5Survey of naturally occurring CD4 <sup>+</sup> T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses2003 · 203 citations